Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12

Cancer Biology and Therapy

Volumn 12, Issue 10, 2011, Pages 881-887

  Tao, Kun ^a   Li, Ya Juan ^a   Wang, Dong ^a   Qi, Jie Yu ^a   Deng, Yi Ping ^a   Wang, Hai Xia ^a   Hu, Jing ^a   Feng, Wen Li ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

BCR ABL; Chronic myelogenous leukemia; Cytotoxic t lymphocytes; DNA vaccine; GPI; Immunotherapy; mIL 12

Indexed keywords

BCR ABL PROTEIN; CANCER VACCINE; GAMMA INTERFERON; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED BCR ABL PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; INTERLEUKIN 12; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER IMMUNIZATION; CANCER INFILTRATION; CELL PROLIFERATION; CELL SURFACE; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENETIC TRANSCRIPTION; IN VITRO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PLASMID; PROTEIN EXPRESSION; SPLEEN CELL; TUMOR IMMUNITY;

ANIMALS; BONE MARROW TRANSPLANTATION; CANCER VACCINES; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FUSION PROTEINS, BCR-ABL; GENETIC VECTORS; GLYCOSYLPHOSPHATIDYLINOSITOLS; IMMUNITY, CELLULAR; INTERLEUKIN-12; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED BALB C; TRANSFECTION;

EID: 81555195467     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.10.17674     Document Type: Article

References (28)

1. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5:881-887; PMID:15719031; http://dx.doi.org/10. 1038/nrc1567
2. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247:1079-82; PMID:2408149; http://dx.doi.org/10.1126/science.2408149
3. Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98:2887-93; PMID:11698267; http://dx.doi.org/10.1182/blood.V98.10.2887
4. Grünebach F, Mirakaj V, Muller MR, Brummendorf T, Brossart P. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. Cancer Res 2006; 66:5892-900; PMID:16740729; http://dx.doi.org/10.1158/0008-5472.CAN- 05-2868
5. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101:2290-6; PMID:9593785; http://dx.doi.org/10.1172/JCI488
6. Sun JY, Krouse RS, Forman SJ, Senitzer D, Sniecinski I, Chatterjee S, et al. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Cancer Res 2002; 62:3175-83; PMID:12036931
7. Shashidharamurthy R, Bozeman EN, Patel J, Kaur R, Meganathan J, Selvaraj P. Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development. Med Res Rev 2011; PMID:21241001; http://dx.doi.org/10.1002/med.20237
8. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85:2680-4; PMID: 7742526
9. Boissel N, Rousselot P, Raffoux E, Cayuela JM, Maarek O, Charron D, et al. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 2004; 18:1656-61; PMID: 15343347; http://dx.doi.org/10.1038/sj.leu.2403474
10. Dong R, Cwynarski K, Entwistle A, Marelli-Berg F, Dazzi F, Simpson E, et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood 2003; 101:3560-7; PMID:12506035; http://dx.doi.org/10.1182/blood-2002-06-1841
11. Sin JI, Kim JJ, Arnold RL, Shroff KE, McCallus D, Pachuk C, et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol 1999; 162:2912-21; PMID:10072541
12. Portielje JE, Kruit WH, Eerenberg AJ, Schuler M, Sparreboom A, Lamers CH, et al. Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant. Cancer Immunol Immunother 2005; 54:37-43; PMID:15693137; http://dx.doi.org/10. 1007/s00262-004-0574-0
13. Rodolfo M, Colombo MP. Interleukin-12 as an adjuvant for cancer immunotherapy. Methods 1999; 19:114-20; PMID:10525447; http://dx.doi.org/10. 1006/meth.1999.0836
14. Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001; 19:3836-47; PMID:11559721
15. Ikezawa H. Glycosylphosphatidylinositol (GPI)-anchored proteins. Biol Pharm Bull 2002; 25:409-17; PMID:11995915; http://dx.doi.org/10.1248/bpb.25.409
16. Ji J, Li J, Holmes LM, Burgin KE, Yu X, Wagner TE, et al. Synergistic anti-tumor effect of glycosylphosphatidylinositol- anchored IL-2 and IL-12. J Gene Med 2004; 6:777-85; PMID:15241785; http://dx.doi.org/10.1002/jgm.547
17. McHugh RS, Nagarajan S, Wang YC, Sell KW, Selvaraj P. Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. Cancer Res 1999; 59:2433-7; PMID:10344754
18. Nagarajan S, Selvaraj P. Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response. Cancer Res 2002; 62:2869-74; PMID:12019166
19. Zhao F, Dou J, Wang J, Chu L, Tang Q, Wang Y, et al. Investigation on the anti-tumor efficacy by expression of GPI-anchored mIL-21 on the surface of B16F10 cells in C57BL/6 mice. Immunobiology 2010; 215:89-100; PMID:19457579; http://dx.doi.org/10.1016/j.imbio.2009.02.003
20. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI- 571 inhibition of abelson tyrosine kinase. Science 2000; 289:1938-42; PMID:10988075; http://dx.doi.org/10.1126/science.289.5486. 1938
21. Osman Y, Takahashi M, Zheng Z, Koike T, Toba K, Liu A, et al. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 1999; 13:166-74; PMID:10025889; http://dx.doi.org/10.1038/sj.leu.2401311
22. Schwartz J, Pinilla-Ibarz J, Yuan RR, Scheinberg DA. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. Semin Hematol 2003; 40:87-96; PMID:12563615; http://dx.doi.org/10.1016/S0037-1963(03)70046-8
23. Englund PT. The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors. Annu Rev Biochem 1993; 62:121-38; PMID:8352586; http://dx.doi.org/10.1146/annurev.bi.62.070193.001005
24. Bütikofer P, Malherbe T, Boschung M, Roditi I. GPI-anchored proteins: now you see 'em, now you don't. FASEB J 2001; 15:545-8; PMID:11156970; http://dx.doi.org/10.1096/fj.00-0415hyp
25. Caras IW, Weddell GN. Signal peptide for protein secretion directing glycophospholipid membrane anchor attachment. Science 1989; 243:1196-8; PMID: 2466338; http://dx.doi.org/10.1126/science.2466338
26. van der Schoot CE, Huizinga TW, van't Veer-Korthof ET, Wijmans R, Pinkster J, von dem Borne AE. Deficiency of glycosyl-phosphatidylinositol-linked membrane glycoproteins of leukocytes in paroxysmal nocturnal hemoglobinuria, description of a new diagnostic cytofluorometric assay. Blood 1990; 76:1853-9; PMID:2145990
27. Shi M, Su L, Hao S, Guo X, Xiang J. Fusion hybrid of dendritic cells and engineered tumor cells expressing interleukin-12 induces type 1 immune responses against tumor. Tumori 2005; 91:531-8; PMID: 16457153
28. Li S, Ilaria RL, Jr., Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189:1399-412; PMID:10224280; http://dx.doi.org/10. 1084/jem.189.9.1399